Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Orano Med LLC
Taiho Oncology, Inc.
Prelude Therapeutics
Nuvation Bio Inc.
Quadriga Biosciences, Inc.
Novartis
Celgene
Tocagen Inc.
AbbVie
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Pharmacyclics LLC.